IVD Raw Materials Market Report 2026

The ivd raw materials market size has grown strongly in recent years. It will grow from $27.47 billion in 2025 to $30.16 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to growth in clinical diagnostic testing volumes, increasing adoption of immunoassays, expansion of molecular diagnostics, rising demand for early disease detection, established use of enzymes and antibodies in ivd kits.

The ivd raw materials market size is expected to see strong growth in the next few years. It will grow to $43.76 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to rising prevalence of chronic and infectious diseases, increasing investment in precision diagnostics, growth of point-of-care testing, expanding biopharmaceutical r&d activities, rising demand for customized ivd raw materials. Major trends in the forecast period include rising demand for high-purity diagnostic reagents, growing adoption of recombinant antibodies and proteins, expansion of molecular diagnostics raw material usage, increasing focus on quality and batch consistency, supply chain diversification for critical ivd inputs.

The rising prevalence of infectious diseases is expected to drive the growth of the IVD raw materials market in the coming years. Infectious diseases are caused by harmful microorganisms that can be transmitted from one person or organism to another. The increase in infectious diseases is attributed to rapid urbanization, which facilitates their spread by raising population density and putting pressure on sanitation and healthcare systems. IVD raw materials are essential in combating infectious diseases, as they support the development of accurate diagnostic tests for early detection and effective disease management. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. Consequently, the growing prevalence of infectious diseases is fueling the expansion of the IVD raw materials market.

Major companies in the IVD raw materials market are concentrating on developing advanced solutions, such as IVD manufacturing facilities, to enhance regional diagnostic capabilities and promote healthcare self-sufficiency. An IVD (in vitro diagnostic) manufacturing facility is a specialized site where devices and equipment used to diagnose diseases and conditions through laboratory testing of samples outside the human body are designed, manufactured, and tested for quality and regulatory compliance. For example, in January 2024, Colexa Biosensor Limited, a Nigeria-based health technology company, collaborated with Codix Pharma Limited, a Nigeria-based pharmaceutical manufacturing company, to establish Sub-Saharan Africa's first in vitro diagnostics (IVD) manufacturing facility in Lagos. This facility, which manufactures the onpoint blood glucose meter and strips, marks a significant milestone in Africa’s healthcare sector, aiming to tackle the growing prevalence of diabetes and enhance diagnostic access. The facility has an annual production capacity of 3.6 million packs, with the possibility to expand to 10.8 million packs, initially focusing on meeting the needs of West Africa.

In June 2025, Fujirebio Holdings, Inc., a Japan-based in vitro diagnostics (IVD) and life-science technology company, acquired Plasma Services Group, Inc. for an undisclosed amount. Through this acquisition, Fujirebio aimed to enhance its supply chain and reinforce its position as a reliable provider of critical and rare biological raw materials for the global IVD and life-science sectors. Plasma Services Group is a U.S.-based company focused on the collection, screening, and supply of high-quality and rare biological materials such as sera and other samples used for control reagents and calibrators for a broad range of diseases, operating from its FDA-registered and ISO-certified facility in Moorestown, NJ.

Major companies operating in the ivd raw materials market are Merck KGaA, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., LGC Limited, Neogen Corporation, MP Biomedicals, CUSABIO Technology, Fujirebio, Fapon Biotech, ABclonal Technology, Creative Diagnostics, AIVD Biotech Inc., OPERON, Beijing Diagreat Biotechnology Co. Ltd., Biosynth, Aalto Bio Reagents, Angstrom Biotech, Eximio Biotech, Glentham Life Sciences Limited, OYC Americas Inc., NOVA Biologics Inc., Sino Biological Inc., ACROBiosystems, ProSpec-Tany TechnoGene Ltd.

North America was the largest region in the IVD raw materials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ivd raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ivd raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the ivd raw materials market by increasing the cost of imported antibodies, enzymes, and specialty biological buffers used in diagnostic assay manufacturing. Molecular diagnostics and immunochemistry segments are most affected, particularly in north america and asia-pacific where global sourcing of high-grade biological materials is common. However, tariffs have encouraged regional sourcing, local production of critical raw materials, and long-term supply chain resilience, supporting domestic manufacturing capabilities and cost optimization.

The ivd raw materials market research report is one of a series of new reports that provides ivd raw materials market statistics, including ivd raw materials industry global market size, regional shares, competitors with a ivd raw materials market share, detailed ivd raw materials market segments, market trends and opportunities, and any further data you may need to thrive in the ivd raw materials industry. This ivd raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In vitro diagnostics (IVD) raw materials are the essential biological and chemical substances needed for the development and production of diagnostic assays that analyze biological samples outside the human body. These materials help in the detection, measurement, or assessment of analytes in clinical samples for diagnostic, screening, or monitoring purposes.

The primary products in IVD raw materials include antibodies, antigens, enzymes, proteins, biological buffers, and others. Antibodies in IVD raw materials are specialized proteins that detect and bind to specific antigens, allowing for the precise identification of diseases or conditions in diagnostic tests. These encompass technologies such as molecular diagnostics, clinical chemistry, immunochemistry, and others, which are utilized by end users including pharmaceutical and biotechnology companies, diagnostic laboratories, contract research organizations, and others.

The IVD raw materials market consists of sales of protein stabilizers, phosphate-buffered saline, washing buffers, and chelating agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.